Antiemetics

Khiron Opens First Zerenia™ Clinic in Peru, Prescribing High and Low THC Medical Cannabis Products to Patients

Thursday, June 10, 2021 - 2:00pm

Khiron launches first Zerenia medical cannabis clinic, via a strategic partnership with Lima-based Clinica Montesur

Key Points: 
  • Khiron launches first Zerenia medical cannabis clinic, via a strategic partnership with Lima-based Clinica Montesur
    Alvaro Torres, CEO and Director comments, "I am pleased to announce the first expansion of our Zerenia brand beyond Colombia.
  • As part of the strategic partnership, Clinica Montesur will provide clinic infrastructure, including its medical facility, clinic permits, systems, and medical staff, among others.
  • The partnership will leverage Khiron's unique ZereniaTM medical cannabis model, including the Company's medical cannabis education platform, real-world evidence, and standard operating procedures.
  • Patients of the clinic will be able to fill prescriptions for High THC and Low THC (CBD) medical cannabis at ten Farmacia Universal S.A.C.

CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health

Thursday, June 10, 2021 - 1:15pm

Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and other psychoactive substances, and manufactures multiple commercial Cannabidiol (CBD) products in compliance with the 2018 U.S. Farm Bill.

Key Points: 
  • Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and other psychoactive substances, and manufactures multiple commercial Cannabidiol (CBD) products in compliance with the 2018 U.S. Farm Bill.
  • BRC will supply the ingredients and CURE will contribute its formulation development, regulatory, and commercial manufacturing capability, as well as support clinical studies.
  • The partnership will initiate the development of CBD and Tetrahydrocannabinol (THC) oral thin films for CUREs clinical studies targeted at advancing veteran health.
  • BRC is a specialty pharmaceutical company that holds several DEA Registrations and is pioneering the federally legal cannabis space in the USA.

Deep Six CBD Debuts Delta 8 THC Baked Goods, Chocolate Bars Online, Delivery Anywhere in the USA Including NJ, MD, FL, GA, Texas.

Friday, June 4, 2021 - 11:00am

"We've heard the stories from our parents and grandparents," explained Nicholas Kruczaj, cannabis entrepreneur and president of Deep Six CBD.

Key Points: 
  • "We've heard the stories from our parents and grandparents," explained Nicholas Kruczaj, cannabis entrepreneur and president of Deep Six CBD.
  • Delta 8 THC, or THC 8, is an important alternative to medical marijuana for customers who won't, or can't, visit dispensaries.
  • Customers order Delta 8 THC baked goods to their favorite summer spots in Virginia Beach, Orlando & Atlanta ahead of time.
  • THC 8 milk chocolate, dark chocolate, and cookies & cream bars give a much-needed sugar rush.

Chairman of New You, Inc. CBD Acquisition Subsidiary ST Brands to Speak on Panel Entitled "The Companies Driving International Market Growth" at the Benzinga Cannabis Capital Conference, Thursday, June 3

Wednesday, June 2, 2021 - 4:07pm

New You, Inc. (OTCQB: NWYU) wholly-owned subsidiary ST Brands Corp is a capital and growth platform for high potential consumer cannabidiol (CBD) companies that create, develop, market, and sell unique and proprietary products to various segments of the global consumer market.

Key Points: 
  • New You, Inc. (OTCQB: NWYU) wholly-owned subsidiary ST Brands Corp is a capital and growth platform for high potential consumer cannabidiol (CBD) companies that create, develop, market, and sell unique and proprietary products to various segments of the global consumer market.
  • ST Brands applies financial, operational, branding resource infrastructure to deliver turnkey business services and achieve economies of scale in capital, sourcing, production, packaging, and sales.
  • ST Brands acquires scalable cannabis companies with the potential to become sector leaders in the legal cannabis market.
  • The conference will feature an interactive forum of live presentations from top CEOs, investors, and leaders in the cannabis space.

Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti®

Wednesday, June 2, 2021 - 1:30pm

Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.

Key Points: 
  • Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.
  • The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Gimoti in June 2020.
  • We are pleased to announce the issuance of this new U.S. patent which further validates that Gimoti is innovative and novel.
  • The issuance of this patent strengthens the intellectual property protection for Gimoti and supports our commercial efforts to make Gimoti the treatment of choice in the gastroparesis market.

Grapefruit USA, Inc. Issues Update Concerning the Company’s Progress Through the First Five Months of 2021

Tuesday, June 1, 2021 - 11:00am

As a result, Grapefruit now manufactures and markets the worlds first and only maximally bioavailable, time release delivered THC-free, hemp derived CBD topical product.

Key Points: 
  • As a result, Grapefruit now manufactures and markets the worlds first and only maximally bioavailable, time release delivered THC-free, hemp derived CBD topical product.
  • These TV platforms have the potential to reach over 540 million homes in the U.S. and international markets.
  • * On March 1, 2021, the Company announced it had been approached by a Canadian cannabis company to enter into discussions concerning a potential acquisition transaction.
  • We remain committed to providing our shareholders and the public with material information concerning the Company as soon as possible.

Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray

Thursday, May 27, 2021 - 1:30pm

You report side effects related to Evoke Pharma products by calling 1-833-4-GIMOTI (1-833-444-6684) or emailing GIMOTImedinfo@evokepharma.com.

Key Points: 
  • You report side effects related to Evoke Pharma products by calling 1-833-4-GIMOTI (1-833-444-6684) or emailing GIMOTImedinfo@evokepharma.com.
  • The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
  • Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.
  • These forward-looking statements include statements regarding Evokes expectations on the social media marketing campaign.

Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Wednesday, May 26, 2021 - 12:30pm

DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m.

Key Points: 
  • DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m.
  • Investors interested in arranging a virtual meeting with the Companys management during the conference should contact the Jefferies conference coordinator.
  • A webcast of the presentation will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com .
  • Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

Leafreport Releases Findings From Pet CBD Report Showing 56 Percent of Products Have Inaccurate Label Claims

Wednesday, May 19, 2021 - 2:58pm

The rest were off by anywhere from 10.2% to 98.5% from the label.

Key Points: 
  • The rest were off by anywhere from 10.2% to 98.5% from the label.
  • Notably, 56% (31) of the tested products had CBD levels that differed from the label by more than the acceptable 10% variance.
  • Of the total tested products, 22 had no THC, despite companies claiming they contained full-spectrum CBD.
  • One lingering problem is that many products don\xe2\x80\x99t contain the correct amount of CBD,\xe2\x80\x9d said Lital Shafir, the head of product at Leafreport.

NuSachi, Inc. Joins Efforts to Prove THC Safety in Food Products

Tuesday, May 18, 2021 - 3:11pm

"EIHA\'s work is good for the industry and the forthcoming insights are sorely needed to help shape public policy and inform regulatory bodies everywhere to make more responsible decisions around THC thresholds for products derived from the plant.

Key Points: 
  • "EIHA\'s work is good for the industry and the forthcoming insights are sorely needed to help shape public policy and inform regulatory bodies everywhere to make more responsible decisions around THC thresholds for products derived from the plant.
  • "\nThe EIHA is investing nearly US $2 million dollars in its THC study on human beings with trials already underway and preliminary results expected this summer.
  • NuSachi offers expertise and services spanning genetics, plant material, extracts, custom formulations, white labeling, and comprehensive turnkey solutions.
  • NuSachi is based in Nashville, Tenn. and can be found online at nusachi.com or via social media @nusachihemp .\n'